Plasma levels of HBV pregenomic RNA before and after nucleos(t)ide analogue treatment

被引：0
|
作者：
Jansen, Louis [1 ,2 ]
van Dort, Karel A. [1 ]
Zaaijer, Hans L. [3 ]
Kootstra, Neeltje A. [1 ]
Reesink, Hendrik W. [2 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Virol, NL-1105 AZ Amsterdam, Netherlands
来源：
HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1079
引用
收藏
页码：729A / 730A
页数：2
相关论文
共 50 条
  • [1] Serum hepatitis B virus DNA and pregenomic RNA levels and kinetics in nucleos(t)ide analogue treated and untreated subjects
    Butler, E.
    Gersch, J.
    Mcnamara, A.
    Kuhns, M.
    Cloherty, G.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S524 - S524
  • [2] Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels
    Deng, Rui
    Fan, Rong
    Sun, Jian
    JOURNAL OF HEPATOLOGY, 2022, 77 (04) : 1223 - 1224
  • [3] Reply to: "Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels"
    Sonneveld, Milan J.
    Chiu, Shao-Ming
    Chen, Chien-Hung
    Maasoumy, Benjamin
    JOURNAL OF HEPATOLOGY, 2022, 77 (04) : 1224 - 1226
  • [4] PHOSPHORUS LEVELS IN LIVER TRANSPLANT RECIPIENTS UNDER NUCLEOS(T)IDE ANALOGUE TREATMENT
    Sinakos, Emmanouil
    Cholongitas, Evangelos
    Antoniadis, Nikolaos
    Goulis, Ioannis
    Vasiliadis, Themistoklis
    Tsakni, Katerina
    Takoudas, Dimitrios
    Akriviadis, Evangelos
    HEPATOLOGY, 2011, 54 : 624A - 624A
  • [5] USING OFF-TREATMENT HBV DNA LEVELS TO PREDICT ALT RELAPSE AFTER NUCLEOS(T)IDE ANALOGUE DISCONTINUATION: A PROSPECTIVE COHORT STUDY
    Chi, H.
    Cao, J.
    Hansen, B. E.
    Yu, T.
    Cai, S.
    Li, Z.
    Janssen, H. L.
    Peng, J.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S589 - S589
  • [6] Nucleos(t)ide analogue treatment for hbv infections can result in the selection of possible HBV vaccine escape mutants
    Yuen, L.
    Revill, P.
    Soriano, V.
    Sheldon, J.
    Locarnini, S.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S260 - S260
  • [7] Influence factors on HBV relapse after withdrawal of nucleos(t)ide analogues treatment
    Zhang, Ka
    Liang, Yijia
    Sun, Xiahai
    Pan, Feixing
    Xu, Huanqi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 416 - 416
  • [8] Biogenesis of serum HBV RNA and clinical phenomena of serum HBV RNA in chronic hepatitis B patients before and after receiving nucleos(t)ide analogues therapy
    Wu, Liandong
    Yang, Zhenggang
    Zheng, Min
    JOURNAL OF VIRAL HEPATITIS, 2024, 31 (05) : 255 - 265
  • [9] Renal safety of nucleos(t)ide analogue monotherapy in HBV-exposed patients after liver transplantation
    Mrzljak, Anna
    Carey, Ivana
    Knighton, Sarah
    Bruce, Matthew J.
    Horner, Mary
    Considine, Aisling B.
    Aluvihare, Varuna
    O'Grady, John G.
    Heneghan, Michael A.
    Agarwal, Kosh
    Suddle, Abid
    HEPATOLOGY, 2015, 62 : 1058A - 1059A
  • [10] Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
    Jiang, Bei
    Dai, Qinghai
    Liu, Yamin
    Yu, Guangxin
    Mi, Yuqiang
    INFECTIOUS AGENTS AND CANCER, 2022, 17 (01)
12345